deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT00679289

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Phase II Study of the Anti-Ganglioside GD3 Mouse/Human Chimeric Antibody KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

Sponsor: Life Science Pharmaceuticals

Conditions Cutaneous Melanoma Metastatic Melanoma
Interventions HDI KW2871
Updated 9 times since 2017 Last updated: Oct 3, 2022 Started: Mar 28, 2008 Primary completion: Feb 3, 2014 Completion: Feb 3, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00679289, this PHASE2 trial focuses on Cutaneous Melanoma and Metastatic Melanoma and remains completed. Sponsored by Life Science Pharmaceuticals, it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotActive Not Recruiting~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshotUnknown Status~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshotCompleted~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Nov 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  2. Sep 2017 — Mar 2018 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  3. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Life Science Pharmaceuticals
  • Ludwig Institute for Cancer Research
  • University of Chicago
  • University of Pittsburgh
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations